Payment overview · 2025
General Payments
$281.18
18 reported records · 7 companies
Healthcare provider profile · identity verified
Eric Mathis, DO
Allopathic & Osteopathic Physicians|Family Medicine · LAWTON, OK · NPI 1699238105
Verified facts
What the public records show
CMS Open Payments records show Eric Mathis, DO received $281.18 in general payments during 2025 across 18 reported records.
Lilly USA, LLC accounted for 36.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $103.84 | 36.9% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $52.70 | 18.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.51 | 12.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.67 | 11.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.82 | 11.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.62 | 5.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.02 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $281.18 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $89.26 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $89.26 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $52.70 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 202 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 97 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 93 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 103 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
98 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
103 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
97 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
93 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
192 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
202 | 48 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 889 | 273 |
| Lisinopril | Lisinopril | 572 | 172 |
| Amlodipine Besylate | Amlodipine Besylate | 488 | 145 |
| Losartan Potassium | Losartan Potassium | 382 | 115 |
| Levothyroxine Sodium | Levothyroxine Sodium | 359 | 89 |
| Gabapentin | Gabapentin | 356 | 104 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 356 | 94 |
| Furosemide | Furosemide | 352 | 104 |
| Hydrochlorothiazide | Hydrochlorothiazide | 352 | 96 |
| Metformin Hcl Er | Metformin Hcl | 344 | 88 |
| Omeprazole | Omeprazole | 296 | 83 |
| Meloxicam | Meloxicam | 284 | 90 |
| Tamsulosin Hcl | Tamsulosin Hcl | 279 | 74 |
| Potassium Chloride | Potassium Chloride | 261 | 86 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 250 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 248 | 70 |
| Metformin Hcl | Metformin Hcl | 239 | 74 |
| Metoprolol Tartrate | Metoprolol Tartrate | 229 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 228 | 76 |
| Montelukast Sodium | Montelukast Sodium | 214 | 56 |
| Glipizide | Glipizide | 208 | 47 |
| Eliquis | Apixaban | 202 | 48 |
| Trulicity | Dulaglutide | 192 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 171 | 56 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 167 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 156 | 46 |
| Trazodone Hcl | Trazodone Hcl | 150 | 41 |
| Sertraline Hcl | Sertraline Hcl | 147 | 39 |
| Alendronate Sodium | Alendronate Sodium | 143 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 141 | 73 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 135 | 69 |
| Citalopram Hbr | Citalopram Hydrobromide | 133 | 37 |
| Carvedilol | Carvedilol | 128 | 39 |
| Ozempic | Semaglutide | 128 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 128 | 36 |
| Simvastatin | Simvastatin | 128 | 39 |
| Diclofenac Sodium | Diclofenac Sodium | 125 | 56 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 103 | 33 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 103 | 18 |
| Synthroid | Levothyroxine Sodium | 98 | 26 |
| Ezetimibe | Ezetimibe | 97 | 32 |
| Jardiance | Empagliflozin | 97 | 40 |
| Mounjaro | Tirzepatide | 93 | 15 |
| Tramadol Hcl | Tramadol Hcl | 93 | 20 |
| Allopurinol | Allopurinol | 90 | 27 |
| Glimepiride | Glimepiride | 90 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 74 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 29 |
| Famotidine | Famotidine | 71 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 63 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 61 | 16 |
| Memantine Hcl | Memantine Hcl | 60 | 18 |
| Atenolol | Atenolol | 59 | 15 |
| Spironolactone | Spironolactone | 59 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 58 | 11 |
| Pregabalin | Pregabalin | 57 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 21 |
| Ibandronate Sodium | Ibandronate Sodium | 52 | 14 |
| Nitroglycerin | Nitroglycerin | 52 | 19 |
| Clonidine Hcl | Clonidine Hcl | 51 | 24 |
| Fenofibrate | Fenofibrate Nanocrystallized | 51 | 14 |
| Bupropion Xl | Bupropion Hcl | 50 | 14 |
| Buspirone Hcl | Buspirone Hcl | 50 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 50 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 16 |
| Celecoxib | Celecoxib | 47 | 16 |
| Donepezil Hcl | Donepezil Hcl | 47 | 15 |
| Alprazolam | Alprazolam | 46 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 46 | 12 |
| Novolog Flexpen | Insulin Aspart | 44 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 43 | 15 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 42 | suppressed |
| Baclofen | Baclofen | 42 | suppressed |
| Clonazepam | Clonazepam | 42 | 11 |
| Lovastatin | Lovastatin | 40 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | 12 |
| Azithromycin | Azithromycin | 39 | 37 |
| Mirtazapine | Mirtazapine | 39 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | suppressed |
| Primidone | Primidone | 39 | 13 |
| Torsemide | Torsemide | 38 | 11 |
| Cephalexin | Cephalexin | 37 | 33 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 13 |
| Finasteride | Finasteride | 36 | suppressed |
| Prednisone | Prednisone | 36 | 29 |
| Fenofibrate | Fenofibrate | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | suppressed |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 35 | 16 |
| Lorazepam | Lorazepam | 34 | 12 |
| Naproxen | Naproxen | 34 | 11 |
| Varenicline Tartrate | Varenicline Tartrate | 34 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | 12 |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 29 |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 23 |
| Estradiol | Estradiol | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 18 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Nystatin | Nystatin | 20 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 19 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 12 |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $281.18 · 18 records | Lilly USA, LLC | ABRYSVO, AIRSUPRA, Cologuard Collection Kit, ELIQUIS, JARDIANCE, MOUNJARO, NURTEC ODT, PREVNAR 20, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA, VRAYLAR, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error